The evidence for the use of recombinant factor VIIa in massive bleeding: revision of the transfusion policy framework

In 2006, the Canadian National Advisory Committee on Blood and Blood Products (NAC) developed a transfusion policy framework for the use of off-label recombinant factor VIIa (rFVIIa) in massive bleeding. Because the number of randomised controlled trials has doubled, the NAC undertook a review of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Y, Moltzan, C J, Anderson, D R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2012
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3546370/
https://www.ncbi.nlm.nih.gov/pubmed/22630348
http://dx.doi.org/10.1111/j.1365-3148.2012.01164.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3546370/
https://www.ncbi.nlm.nih.gov/pubmed/22630348
http://dx.doi.org/10.1111/j.1365-3148.2012.01164.x

Ejemplares similares